The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis

Who May Qualify: - Patients aged 18-55 years, inclusive - Diagnosis of RRMS (McDonald Criteria 2017 and Lublin phenotype classification 2014) - Expanded disability status scale (EDSS) score less than or equal to 5.5 - Patients receiving a first line treatment with teriflunomide or dimethyl fumarate at a stable dose, for at least 24 weeks, or patients who are not receiving treatment because they do not want to receive a DMT after the investigator has informed them of their possible respective benefits and possible adverse events - At enrollment, the patient is not expected to require a change in DMT - Patients showing a maximum of two new lesions on MRI prior to inclusion - Females of childbearing potential must have a negative urine pregnancy test result prior to initiation of study product - For females of childbearing potential: agreement to use adequate contraceptive methods during the treatment period - Ability to comply with the study protocol - Patients must sign and date a written willing to sign a consent form prior to entering the study Who Should NOT Join This Trial: - Relapse the month before enrollment - Presence of a new lesion, indicative of radiological activity, on the MRI performed before starting the study - Use of corticosteroids the month before enrollment - Use of antibiotics three months before enrollment - Taking other forms of symbiotic, probiotic, prebiotic and postbiotic supplements three months before enrollment - Patients suffering from any type of bowel disease - Pregnant or breastfeeding or intending to become pregnant during the study. - Be menopausal - Be a smoker Always talk to your doctor about whether this trial is right for you.